DLG3 and gastric cancer: In addition to the Hippo pathway, DLG3 can also inhibit the activation of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway (Liu et al., 2021), and the PI3K/AKT signaling pathway is implicated in the occurrence and progression of GC (Chen et al., 2020b).